Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05
- Registration Number
- NCT01725269
- Lead Sponsor
- Aires Pharmaceuticals, Inc.
- Brief Summary
The AIR001-CS05 study evaluated the safety and efficacy (effectiveness) of AIR001 over 16 weeks in subjects who have PAH. The purpose of the AIR001-CS06 study is to evaluate the intermediate / long-term safety of AIR001 in subjects who have completed the AIR001-CS05 study. Assessments to evaluate the effectiveness of the study drug will include measurements of exercise ability and evaluations of PAH disease symptoms.
- Detailed Description
The primary objective of this study is to evaluate the intermediate/long-term safety of inhaled nebulized AIR001 administered according to 3 treatment arms (80 milligrams (mg) 4 times daily, 46 mg 4 times daily, or 80 mg once daily) in subjects with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH) who have completed the 16-week AIR001-CS05 study.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 17
- Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study prior to initiation of any subject-mandated procedures.
- Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Has completed the 16-week AIR001-CS05study as planned.
- If on corticosteroids, has been receiving a stable dose of less than or equal to 20 mg/day of prednisone (or equivalent dose, if other corticosteroid) for at least 1 month (30 days) prior to the AIR001-CS05 study Baseline/Day 1 visit. If receiving treatment for Connective Tissue Disease (CTD) with any other drugs, doses should remain stable, if clinically feasible, for the duration of the AIR001-CS06 study.
- Women of childbearing potential must be using at least one form of medically acceptable contraception (i.e. either oral, topical, implanted hormonal contraceptives, or an intrauterine device) or two barrier methods; have a negative pregnancy test at Screening and Baseline/Day 1 and agree to use reliable methods of contraception until at least 24-hours after the last dose of study drug. Women who are surgically sterile (i.e. hysterectomy, bilateral oophorectomy, or tubal ligation) or those who are post-menopausal for at least 2 years are not considered to be of childbearing potential. Men who are not sterile (i.e. have not had a vasectomy) must also agree to use contraception until at least 24-hours after the last dose of study drug.
-
Participation in a device or other interventional clinical studies (other than AIR001-CS05), within 1 month (30 days) of Baseline/Day 1 and/or during study participation.
-
Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure > 160 mmHg or sitting diastolic blood pressure > 100 mmHg during Baseline/Day 1 visit.
-
Systolic blood pressure < 90 mmHg at Baseline/Day 1.
-
Diagnosis of Down syndrome.
-
Moderate to severe hepatic impairment classified as a Child-Pugh Class B or C at Baseline/Day 1.
-
Has chronic renal insufficiency as defined by serum creatinine > 2.5 mg/dL or has an estimated Glomerular Filtration Rate (eGFR) < 30 mL/min at Baseline/Day 1, or requires dialytic support.
-
Has a hemoglobin (Hgb) concentration < 8.5 g/dL at Baseline/Day 1.
-
Personal or family history of the following:
- Congenital or acquired methemoglobinemia;
- RBC CYPB5 reductase deficiency.
-
History of glucose-6-phosphate dehydrogenase (G6PD) deficiency or any contraindication to receiving methylene blue.
-
For subjects with Human immunodeficiency virus (HIV) associated PAH, requirement for the use of inhaled pentamidine.
-
The use of oral or topical nitrates (nitroglycerin, glyceryl trinitrate (GTN), isosorbide dinitrate, and isosorbide mononitrate) within 1 month (30 days) prior to Baseline/Day 1 or throughout the AIR001-CS06 study until EOS or Termination visit. Note: Intravenous GTN in an emergency setting may be administered by starting with a low dose and titrating upward, while the subject is being monitored closely for changes in blood pressure and heart rate.
-
Known or suspected hypersensitivity or allergic reaction to sodium nitrite or sodium nitrate.
-
History of malignancy within 5-years prior to Baseline/Day 1 of the AIR001-CS05 study, with the exception of localized non-metastatic basal cell carcinoma of the skin and in situ carcinoma of the cervix.
-
Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
-
Has a psychiatric, addictive or other disorder that compromises the ability to give informed consent for participating in this study. This includes subjects with a recent history of abusing alcohol or illicit drugs 1 month (30 days) prior to study Baseline/Day 1 of the AIR001-CS05 study and for the duration of the study.
-
Is currently pregnant or breastfeeding or intends to become pregnant during the duration of the study.
-
Investigators, study staff or their immediate families.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 46 mg AIR001, nebulized four times daily AIR001 AIR001, 46 mg into nebulizer 80mg AIR001, nebulized once daily AIR001 AIR001, 80 mg into nebulizer 80mg AIR001, nebulized four times daily AIR001 AIR001, 80 mg into nebulizer
- Primary Outcome Measures
Name Time Method To evaluate the intermediate/long-term safety of inhaled nebulized AIR001 minimum of 6 months The primary objective of this study is to evaluate the intermediate/long-term safety of inhaled nebulized AIR001 administered according to 3 treatment arms (80 milligrams (mg) 4 times daily, 46 mg 4 times daily, or 80 mg once daily) in subjects with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH) who have completed the 16-week AIR001-CS05 study.
- Secondary Outcome Measures
Name Time Method To assess the effect of inhaled AIR001 on Time to Clinical Worsening, 6MWD, Functional Class, and Quality of Life minimum of 6 months The secondary objectives of this study are to evaluate the effect of inhaled nebulized AIR001 administered according to 3 different treatment arms (80 mg 4 times daily, 46 mg 4 times daily, or 80 mg once daily) in subjects with WHO Group 1 PAH who completed the 16-week AIR001-CS05 study, as determined by time to the first morbidity/mortality event as defined in Time to Clinical Worsening (TTCW) assessments and by change from Baseline in AIR001-CS05 to the 40th week from the start of AIR001 nebulization in AIR001-CS05 (Week 24 of AIR001-CS06) and End of Study (EOS) or Termination visit of AIR001-CS06 in the following:6-Minute Walk Distance (6MWD) assessed at peak, WHO/NYHA Functional Class, Quality of Life (QOL) as measured by SF-36,Borg Dyspnea Index,6MWD assessed at trough
Trial Locations
- Locations (25)
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States
University of Cincinnati
🇺🇸Cincinnati, Ohio, United States
University of Szeged
🇭🇺Szeged, Hungary
UCSD Medical Center
🇺🇸La Jolla, California, United States
University of Maryland Medical Center
🇺🇸Baltimore, Maryland, United States
Adaani Frost, M.D.
🇺🇸Houston, Texas, United States
Kentuckiana Pulmonary Associates
🇺🇸Louisville, Kentucky, United States
The Alfred Hospital
🇦🇺Melbourne, Victoria, Australia
University of Debrecen
🇭🇺Debrecen, Hungary
UCLA Medical Center
🇺🇸Torrance, California, United States
Inova Fairfax Hospital
🇺🇸Falls Church, Virginia, United States
St. Vincent's Hospital
🇦🇺Darlinghurst, New South Wales, Australia
Gottsegen Gyorgy Hungarian
🇭🇺Budapest, Hungary
Washington University School of Medicine
🇺🇸St. Louis, Missouri, United States
University of Texas Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Semmelweis University
🇭🇺Budapest, Hungary
Boston University School of Medicine
🇺🇸Boston, Massachusetts, United States
University of Colorado Denver
🇺🇸Aurora, Colorado, United States
The Ohio State University Medical Center
🇺🇸Columbus, Ohio, United States
Tufts Medical Center
🇺🇸Boston, Massachusetts, United States
Royal Hobart Hospital
🇦🇺Hobart, Tasmania, Australia
The Prince Charles Hospital
🇦🇺Chermside, Queensland, Australia
Aurora St. Luke's Medical Center
🇺🇸Milwaukee, Wisconsin, United States